carfilzomib

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adult Nasal Type Extranodal NK/T-cell Lymphoma

Conditions

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma

Trial Timeline

Jun 21, 2011 → Mar 1, 2018

NCT ID

NCT01336920

About carfilzomib

carfilzomib is a phase 1 stage product being developed by Amgen for Adult Nasal Type Extranodal NK/T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01336920. Target conditions include Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma.

What happened to similar drugs?

9 of 20 similar drugs in Adult Nasal Type Extranodal NK/T-cell Lymphoma were approved

Approved (9) Terminated (2) Active (11)

✅BenralizumabAstraZenecaApproved

✅FluMist + inactivated influenza vaccineAstraZenecaApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved

✅Aztreonam lysineGilead SciencesApproved

✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved

✅SabrilLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01410500	Pre-clinical	Completed	—	—	Multiple Myeloma
NCT02970747	Pre-clinical	Completed	Oct 25, 2016	Apr 26, 2025	Multiple Myeloma in Relapse
NCT02318784	Phase 2	Completed	Jul 15, 2015	May 15, 2021	Neuroendocrine Cancer
NCT02302495	Phase 2	Completed	Jan 8, 2014	Jul 31, 2021	Multiple Myeloma
NCT01949532	Phase 1	Completed	Jan 1, 2014	Jan 1, 2017	Relapsed Multiple Myeloma
NCT01949545	Phase 1	Completed	Oct 1, 2013	Sep 1, 2015	Solid Tumors
NCT01775553	Phase 2	Completed	Sep 1, 2013	May 1, 2016	Relapse Multiple Myeloma
NCT01336920	Phase 1	Completed	Jun 21, 2011	Mar 1, 2018	Adult Nasal Type Extranodal NK/T-cell Lymphoma
NCT01351623	Phase 2	Completed	May 9, 2011	Jan 26, 2016	Multiple Myeloma
NCT01212380	Phase 1	Completed	Oct 1, 2010	Sep 1, 2015	B-cell Chronic Lymphocytic Leukemia
NCT00884312	Phase 2	Completed	Apr 9, 2009	May 17, 2017	Multiple Myeloma
NCT00721734	Phase 2	Completed	Nov 1, 2008	Nov 1, 2012	Multiple Myeloma
NCT00530816	Phase 2	Completed	Sep 1, 2007	Jul 1, 2013	Multiple Myeloma

Competing Products

20 competing products in Adult Nasal Type Extranodal NK/T-cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
Daridorexant + Placebo	Idorsia	Phase 1	23
SON-1010 (IL12-FHAB)	Sonnet BioTherapeutics	Phase 1	23
Somatropin	Eli Lilly	Phase 3	40
agenT-797	MiNK Therapeutics	Phase 1	19
Pegilodecakin	Eli Lilly	Phase 1	29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab	eFFECTOR Therapeutics	Phase 1/2	29
Lazertinib(G001) + Lazertinib(G002)	Yuhan	Phase 1	29
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	29
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	35
Roxadustat	Astellas Pharma	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
E7389 + E7389 + E7389	Eisai	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
E2022 + E2022 + E2022 + E2022 + E2022	Eisai	Phase 1	29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	29